(R)-2-(((4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoyl)oxy)-3-(stearoyloxy)propyl (2-(trimethylammonio)ethyl) phosphate | 59403-52-0

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 甘油磷脂
• 英文名称: (R)-2-(((4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoyl)oxy)-3-(stearoyloxy)propyl (2-(trimethylammonio)ethyl) phosphate
• 英文别名: 1-octadecanoyl-2-(4Z,7Z,10Z,13Z,16Z,19Z-docosahexaenoyl)-sn-glycero-3-phosphocholine；18:0/22:6-phosphatidylcholine；1-stearoyl-2-docosahexaenoyl-sn-glycero-3-phosphocholine；PC(18:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))；sn-1 18:0 sn-2 22:6 PC；18:0-22:6 PC；[(2R)-2-[(4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoyl]oxy-3-octadecanoyloxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
• CAS: 59403-52-0
• 化学式: C₄₈H₈₄NO₈P
• 分子量: 834.171
• InChiKey: FAUYAENFVCNTAL-PFFNLMTBSA-N

物化性质

• 溶解度：
  氯仿：可溶
• 物理描述：
  Solid

计算性质

• 辛醇/水分配系数(LogP)：
  13.6
• 重原子数：
  58
• 可旋转键数：
  42
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  111
• 氢给体数：
  0
• 氢受体数：
  8

安全信息

• WGK Germany：
  3

反应信息

• 作为反应物：
  描述：

  (R)-2-(((4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoyl)oxy)-3-(stearoyloxy)propyl (2-(trimethylammonio)ethyl) phosphate 在 Tris-HCl buffer 、 sodium salt of choleic acid 、 phosphalipase C 、 calcium chloride 作用下， 生成 1-Stearoyl-2-docosahexaenoyl-sn-glycerol
  参考文献：
  名称：

  Enzymatic Synthesis of Phosphatidylinositol Bearing Polyunsaturated Acyl Group

  摘要：

  开发了一种合成具有多不饱和脂肪酰基的磷脂酰肌醇（PI）的新路线，采用脂肪酶和磷脂酶C作为生物催化剂，以补充正常的化学反应。

  DOI：

  10.1271/bbb.60.1916
• 作为产物：
  描述：

  硬脂酸酯乙烯基 在 palladium dihydroxide 4-二甲氨基吡啶 、 水 、 氢气 、 N,N'-二环己基碳二亚胺 、 lipase 、 三氯氧磷 作用下， 以 氯仿 、 异丙醇 为溶剂， 生成 (R)-2-(((4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoyl)oxy)-3-(stearoyloxy)propyl (2-(trimethylammonio)ethyl) phosphate
  参考文献：
  名称：

  Enzymatic Synthesis of Phosphatidylinositol Bearing Polyunsaturated Acyl Group

  摘要：

  开发了一种合成具有多不饱和脂肪酰基的磷脂酰肌醇（PI）的新路线，采用脂肪酶和磷脂酶C作为生物催化剂，以补充正常的化学反应。

  DOI：

  10.1271/bbb.60.1916

文献信息

• Novel neutral (bio)material
  申请人：Centre National de la Recherche Scientifique (CNRS)

  公开号：EP2444464A1

  公开（公告）日：2012-04-25

  The instant invention concerns - a method for preparing a material comprising the following steps of a) treating the support to obtain a layer having SiH function, b) grafting the SiH layer obtained in step a) with an alkene and a catalyst for covalently bonding the alkene to the coating, said alkene being non-terminal and/or having an hydrophilic part, and c) recovering a material comprising a support coated with a chain covalently grafted with Si-C bonds, - a material comprising a support, optionally comprising a polyhydrosiloxane layer, on which surface is covalently bonded a grafted chain, wherein the covalent bonding between the support and/or the polyhydrosiloxane and the chain is an Si-C bond, and the grafted chain is bonded through a non-terminal carbon, through more than one covalent bond and/or the chain is having at least one hydrophilic part, and - devices comprising such material.

  本发明涉及 - 一种制备材料的方法，包括以下步骤 a) 处理支持物以获得具有 SiH 功能的层；b) 将步骤 a) 中获得的 SiH 层与烯烃和催化剂接枝，以将烯烃共价键合到涂层上，所述烯烃为非末端烯烃和/或具有亲水部分；以及 c) 回收一种材料，该材料包括涂有共价键合的 Si-C 键接枝链的支持物、 - 一种材料，包括支撑体，可选择包括聚氢硅氧烷层，在支撑体表面共价键合了一条接枝链，其中支撑体和/或聚氢硅氧烷与链之间的共价键合是 Si-C 键，接枝链通过非末端碳键、通过一个以上的共价键和/或链具有至少一个亲水部分键合，以及 - 包括这种材料的装置。
• DISRUPTION OF THE INTERACTION BETWEEN AMYLOID BETA PEPTIDE AND DIETARY LIPIDS
  申请人：The Trustees of Columbia University in the City of New York

  公开号：US20170354669A1

  公开（公告）日：2017-12-14

  The present invention relates to methods of treating neurodegenerative disorders associated with Alzheimer's disease (AD), Parkinson's disease (PD) and synucleinopathies, such as dementia with Lewy bodies, Down Syndrome (DS) and associated cognitive disorders, multiple system atrophy, and rare neuroaxonal dystrophies, such as Niemann-Pick type C disease (NPC) and Gaucher's disease comprising administering an inhibitor to disrupt the interaction between Aβ or αS and neuronal lipids. The invention further relates to assays for identifying agents that reduce interaction between Aβ or αS and neuronal lipids. Lastly, the invention relates to methods and compositions for intranasal administration of fatty acids or lipids containing fatty acid acyl chains of dietary lipids for promoting central nervous system health and/or prevention or treatment of neurodegenerative disorders.